• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

    2/5/21 8:31:00 AM ET
    $CVLB
    Get the next $CVLB alert in real time by email

    NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer.

    Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of cross-functional business initiatives.

    “Marc’s extensive financial knowledge, operational experience, and business analytics capabilities are a great fit with our growing team of industry experts,” commented Justin Schreiber, CEO of Conversion Labs. “His senior-level financial experience at a NYSE-listed company involved in eCommerce also fits well with our rapidly growing direct-to-consumer telemedicine business. We expect Marc’s contributions to prove invaluable as we work to advance Conversion Labs to its next level of operational growth and expansion.”

    For the past seven years, Benathen has served as senior vice president and chief financial officer at Blink Fitness, a fast-growing national fitness company with both traditional gym locations and digital offerings. He served as an integral member of Blink’s executive committee, which oversaw the growth of the company from 20 to 107 locations nationwide. He also led the ground-up build of the finance and operational departments reporting to him.

    At Blink, he was responsible for leading numerous financial and strategic initiatives during his tenure, including multi-hundred-million-dollar capital market transactions, M&A, joint ventures, and pricing initiatives, and helping to successfully steer the company’s national expansion.

    Prior to Blink, he served as senior manager of corporate finance at Ann, Inc., a $2 billion public specialty women’s retailer with more than 1,000 locations, four divisions (Ann Taylor, LOFT, Ann Taylor Factory, and LOFT Outlet), and e-Commerce and global manufacturing operations. Benathen oversaw a $160 million plan for new store development, remodels, new technology adoption and eCommerce expansion. He co-led a new omni-channel business effort that added $15 million in incremental profits over a two-year period.

    Benathen earlier served as director of financial reporting, planning and analysis at Partsearch Technologies, a private equity-backed consumer electronics and home appliance parts and accessories company. Prior to its acquisition by its largest customer, he led the company’s financial reporting processes, including modeling $10 million in annual savings and significant gross margin expansion as part of a company-wide restructuring.

    “I could not be more impressed by the energy and passion of Conversion Labs’ leadership team, which is evident in the phenomenal growth they’ve been driving over the last year,” stated Benathen. “As the healthcare industry makes a massive shift towards telemedicine and online pharmacy, Conversion Labs continues to be at the forefront of this transition. I’m looking forward to doing my part to support the strong growth outlook ahead in 2021 and beyond.”

    Earlier in his career, Benathen served as manager of finance, accounting and global planning at Fortent, a security and tech company specializing in risk, compliance, and financial crime prevention. He also earlier served as a senior financial analyst for Businessweek, which was a unit of McGraw Hill, the $6 billion public information and media publishing company. He previously served in a similar capacity at NetJets, the leading provider of fractional and private aviation services worldwide and a Berkshire Hathaway portfolio company.

    Benathen earned his Bachelor of Business Administration in finance with honors from Baruch College in New York City. He currently serves on the board of directors of Baruch College Alumni Association, after earlier serving as president and treasurer.

    About Conversion Labs
    Conversion Labs, Inc. is a leading telemedicine company with a portfolio of online direct-to-consumer brands. The company combines virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.

    Important Cautions Regarding Forward-Looking Statements
    This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

    Company Contact                                
    Conversion Labs, Inc.                                                
    Email Contact        

    Media and Investor Relations
    Ron Both or Grant Stude
    CMA Investor Relations
    Tel (949) 432-7566
    Email Contact


    Get the next $CVLB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVLB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVLB
    SEC Filings

    See more
    • SEC Form 8-K filed

      8-K - LifeMD, Inc. (0000948320) (Filer)

      2/26/21 5:00:48 PM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/22/21 7:30:16 AM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/12/21 8:30:10 AM ET
      $CVLB

    $CVLB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: David Happy Walters was granted 1,200,000 units of Common Stock, increasing ownership by 149% to 1,336,300 units

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/26/21 10:04:47 AM ET
      $CVLB
    • SEC Form 4: Harold Eric Yecies bought $100,400 worth of Common Stock (5,000 units at $20.08)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 7:16:47 PM ET
      $CVLB
    • SEC Form 4: Michael Brad Roberts bought $102,500 worth of Common Stock (5,000 units at $20.50)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 6:13:10 PM ET
      $CVLB

    $CVLB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on Conversion Labs with a new price target

      BTIG Research reiterated coverage of Conversion Labs with a rating of Buy and set a new price target of $40.00 from $15.00 previously

      2/18/21 9:19:07 AM ET
      $CVLB
    • B. Riley FBR initiated coverage on Conversion Labs with a new price target

      B. Riley FBR initiated coverage of Conversion Labs with a rating of Buy and set a new price target of $35.00

      2/5/21 6:59:45 AM ET
      $CVLB

    $CVLB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Conversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMD

      NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market today under its new name, LifeMD, Inc., and Nasdaq ticker symbol, LFMD. The stock’s new CUSIP number will be 53216B 104. “Our new name reflects our evolution from a healthcare-focused performance marketing business into a leading provider of personalized, direct to patient telehealth services,” stated Justin Schreiber, LifeMD’s co-founder and CEO. “Our vision is to radically change healthcare by making access to the best physicians and prescription medications easily accessible, convenient, and aff

      2/22/21 3:30:00 AM ET
      $CVLB
    • Conversion Labs to Become Life MD™ with Launch of New Concierge Telehealth Services

      NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, will change its name to Life MD™ on February 22, followed by the official launch of its subscription-based primary care and concierge services offering designed to positively transform all aspects of a patient’s healthcare. “We see our new name reflecting our evolution and expansion from a branded telemedicine products company into a leading provider of end-to-end concierge telehealth services,” stated company co-founder and CEO, Justin Schreiber. “Life MD expresses our desire to have a deeper connection to the daily lives of our patients who desire more conven

      2/12/21 8:30:00 AM ET
      $CVLB
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB

    $CVLB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Conversion Labs, Inc.

      SC 13D - LifeMD, Inc. (0000948320) (Subject)

      3/19/21 4:15:12 PM ET
      $CVLB

    $CVLB
    Leadership Updates

    Live Leadership Updates

    See more
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer

      NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and psychiatrist, Dr. Anthony Puopolo, to the new position of chief medical officer. Dr. Puopolo will be responsible for overseeing the company’s rapidly expanding network of state licensed physicians and ensuring that the company is delivering the highest quality of care. He will also work closely with Conversion Labs’ product and marketing teams to optimize the company’s telemedicine offerings and support expansion into new verticals. Dr. Puopolo brings to Conversion Labs more than 20 years of execut

      1/11/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer

      NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, Bryant Hussey, to the new position of chief digital officer. He will lead the company’s marketing and customer retention efforts, as well as help launch new or enhanced telemedicine products, improve unit economics, and maximize patient lifetime value. Hussey brings to Conversion Labs more than 20 years of executive experience at direct-to-consumer and eCommerce companies, translating business goals into successful marketing campaigns. He specializes in lead generation, funnel optimization and custo

      1/5/21 10:15:00 AM ET
      $CVLB